The current research aimed to evaluate the hospitalized COVID-19 Patients’ characteristics, comorbidities, and outcomes. The present hospital-based study was executed in the COVID-19 units of Aljouf province. A simple random sampling method was applied to include the 400 patients’ files and all the relevant data was collected. The association between the COVID-19 outcome with sociodemographic characteristics, comorbidities, and immune status was assessed using the chi-square test. A p-value <0.05 was taken as statistically significant. The common symptoms were fever (54.5%), followed by cough (47.8%), and shortness of breath (47.3%). The commonest comorbidity was diabetes mellitus (43.5%). Of the 400 patients, 77.3% had recovered without any complications, 4.5% had one or more complications, and mortality was 18.3%. The COVID-19 outcome (complete recovery, recovery with complications, and death) were significantly associated with age (p<0.001), immune status (p=0.001), diabetes (p=0.001), hypertension (p=0.001), IHD (p=0.025), CKD (p=0.001), and cardiac failure (p=0.008). Most of the patients (77.3%) recovered completely and a mortality rate of 18.3% was observed in our study. This study confirms that patients afflicted with co-morbid conditions like diabetes, hypertension, IHD, CKD, and cardiac failure are highly susceptible to poor outcomes.
1. Phan T. Novel coronavirus: From discovery to clinical diagnostics. Infection, Gena Evol. 2020;79:104211.
2. Li J, Lai S, Gao GF, Shi W. The emergence, genomic diversity, and global spread of SARS-CoV-2. Nature. 2021;600(7889):408-18.
3. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. NEJM. 2020.
4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
5. Behzad S, Aghaghazvini L, Radmard AR, Gholamrezanezhad A. Extrapulmonary manifestations of COVID-19: radiologic and clinical overview. Clin Imaging. 2020;66:35-41.
6. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052-9.
7. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Critic Care. 2020;24(1):1-4.
8. Garcia-Gonzalez P, Tempio F, Fuentes C, Merino C, Vargas L, Simon V, et al. Dysregulated immune responses in COVID-19 patients correlating with disease severity and invasive oxygen requirements. Front Immunol. 2021;12:769059.
9. Mudatsir M, Fajar JK, Wulandari L, Soegiarto G, Ilmawan M, Purnamasari Y, et al. Predictors of COVID-19 severity: a systematic review and meta-analysis. F1000 Res. 2020;9.
10. Kukar M, Gunčar G, Vovko T, Podnar S, Černelč P, Brvar M, et al. COVID-19 diagnosis by routine blood tests using machine learning. Sci Rep. 2021;11(1):10738.
11. Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med. 2020;180(8):1081-9.
12. Elshazli RM, Toraih EA, Elgaml A, El-Mowafy M, El-Mesery M, Amin MN, et al. Diagnostic and prognostic value of hematological and immunological markers in COVID-19 infection: A meta-analysis of 6320 patients. PloS one. 2020;15(8):e0238160.
13. Gao Z, Xu Y, Sun C, Wang X, Guo Y, Qiu S, et al. A systematic review of asymptomatic infections with COVID-19. JMII. 2021;54(1):12-6.
14. Venter M, Richter K. Towards effective diagnostic assays for COVID-19: a review. J Clin Pathol. 2020;73(7):370-7.
15. CDC, Coronavirus Disease 2019 (COVID-19). Symptoms Centers for Disease Control and Prevention (2019), Retrieved from: https://www.cdc.gov/coronavirus/2019-ncov/index.html
16. Xu J, Xiao W, Liang X, Shi L, Zhang P, Wang Y, et al. A meta-analysis on the risk factors adjusted association between cardiovascular disease and COVID-19 severity. BMC Public Health. 2021;21(1):1-49.
17. Huang JF, Greenway MR, Nasr DM, Chukwudelunzu Sr FE, Demaerschalk BM, O’Carroll CB, et al. Telestroke in the time of COVID-19: the Mayo Clinic experience. InMayo Clinic Proceedings 2020 Aug 1 (Vol. 95, No. 8, pp. 1704-1708). Elsevier.
18. Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022;22(9):1293-302.
19. Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HH, Mercer SW, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Glob Health. 2020;8(8):e1003-17.
20. Tian H, Liu Y, Li Y, Wu CH, Chen B, Kraemer MU, et al. An investigation of transmission control measures during the first 50 days of the COVID-19 epidemic in China. Science. 2020;368(6491):638-42.
21. Giordano G, Blanchini F, Bruno R, Colaneri P, Di Filippo A, Di Matteo A, et al. Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy. Nat Med. 2020;26(6):855-60.
22. Flaxman S, Mishra S, Gandy A, Unwin HJ, Mellan TA, Coupland H, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature. 2020;584(7820):257-61.
23. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. NEJM. 2020;382(10):929-36.
24. Silveira MF, Barros AJ, Horta BL, Pellanda LC, Victora GD, Dellagostin OA, et al. Population-based surveys of antibodies against SARS-CoV-2 in Southern Brazil. Nat Med. 2020;26(8):1196-9.
25. Laxminarayan R, Wahl B, Dudala SR, Gopal K, Mohan BC, Neelima S, et al. Epidemiology and transmission dynamics of COVID-19 in two Indian states. Science. 2020;370(6517):691-7.
26. Massinga Loembé M, Tshangela A, Salyer SJ, Varma JK, Ouma AE, Nkengasong JN. COVID-19 in Africa: the spread and response. Nat Med. 2020;26(7):999-1003.
27. Alguwaihes AM, Al-Sofiani ME, Megdad M, Albader SS, Alsari MH, Alelayan A, et al. Diabetes and Covid-19 among hospitalized patients in Saudi Arabia: a single-centre retrospective study. Cardiovasc Diabetol. 2020;19:1-2.
28. Pham H. Estimating the COVID-19 death toll by considering the time-dependent effects of various pandemic restrictions. Math. 2020;8(9):1628.
29. Liu B, Spokes P, He W, Kaldor J. High risk groups for severe COVID-19 in a whole of population cohort in Australia. BMC Infect Dis. 2021;21(1):1-9.
30. Guan WJ, Liang WH, He JX, Zhong NS. Cardiovascular comorbidity and its impact on patients with COVID-19. ERJ. 2020;55(6).
31. Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Intern Med. 2020;35:1545-9.
32. Wu YC, Chen CS, Chan YJ. Overview of the 2019 novel coronavirus (2019-nCoV). J Chin Med Assoc. 2020;83(3):217-20.
33. Lounis M. A brief review of clinical features of coronavirus disease 2019 (COVID-19) in Algeria. Eur J Public Health. 2021;5(2):em0078.
34. Alharbi AA, Alqassim AY, Muaddi MA, Alghamdi SS, Alharbi A, Muaddi M, et al. Regional differences in COVID-19 mortality rates in the Kingdom of Saudi Arabia: a simulation of the new model of care. Cureus. 2021;13(12).
35. Christanto A, Listyoko AS, Putra NPP. Analysis of comorbidity and its association with disease severity and mortality rate in hospitalized COVID-19 patients. JRI. 2022;42(1):18-25.
36. Choi YJ, Park JY, Lee HS, Suh J, Song JY, Byun MK, et al. Variable effects of underlying diseases on the prognosis of patients with COVID-19. PLoS One. 2021;16(7):e0254258.
37. Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020;55(5).
38. Ezeokpoa CV, Nnolima BI, Anikpoa EA, Onyekachia KE. COVID-19 and Diabetes Mellitus: The Link and Clinical Implications. 2021. Dubai Diabetes Endocrinol J. 2020;26(2):69-77.
39. Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-81.
40. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Retraction: cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. 2020;382(25):e102.
41. Kong KA, Jung S, Yu M, Park J, Kang IS. Association between cardiovascular risk factors and the severity of coronavirus disease 2019: Nationwide epidemiological study in Korea. Front Cardiovasc Med. 2021;8:732518.
42. Yonas E, Alwi I, Pranata R. Effect of heart failure on the outcome of COVID-19—A meta-analysis and systematic review. Am J Emerg Med. 2021;46:204-11.
43. Jdiaa SS, Mansour R, El Alayli A. COVID–19 and chronic kidney disease: an updated overview of reviews. J Nephrol. 2022:1-7.
44. Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, et al. Aspects of immune dysfunction in end-stage renal disease. CJASN. 2008;3(5):1526.